{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T02:47:33Z","timestamp":1786762053447,"version":"build-2736575974"},"reference-count":61,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background\/Objectives: Melanoma is a malignant tumour of melanocytes. Cutaneous melanoma accounts for the vast majority of cases and has benefitted from advances in targeted and immune checkpoint inhibitor therapies, leading to substantial improvements in survival. In contrast, mucosal and vulvovaginal melanomas are rare, aggressive subtypes with distinct molecular and immune profiles and poor prognoses. This review synthesises evidence comparing cutaneous, mucosal, and vulvovaginal melanoma, with emphasis on biology, treatment, and outcomes Methods: A narrative comparative review was undertaken, examining the published literature on the epidemiology, molecular and immune characteristics, and treatment outcomes of cutaneous, mucosal, and vulvovaginal melanoma, including systemic therapies and surgical approaches. Results: Cutaneous melanoma demonstrates high tumour mutational burden and frequent BRAF and NRAS mutations, underpinning the success of targeted therapy and immunotherapy. Mucosal and vulvovaginal melanomas exhibit lower mutational burden, distinct mutation patterns, and reduced immunogenicity, correlating with poorer treatment responses. Surgery remains the mainstay of management, though optimal margins in vulvovaginal melanoma are unclear. Recurrence rates are high, and five-year survival remains poor. Evidence for systemic therapy is limited to small retrospective cohorts and subgroup analyses, showing lower response and survival rates compared with cutaneous melanoma. Chemotherapy has minimal benefit. Conclusions: Mucosal and vulvovaginal melanomas are biologically and clinically distinct from cutaneous melanoma and continue to have poor survival outcomes. Their rarity restricts high-quality evidence, highlighting the need for collaborative, innovative research to inform effective treatment strategies.<\/jats:p>","DOI":"10.3390\/jpm15110551","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T10:56:47Z","timestamp":1762945007000},"page":"551","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparative Insights into Cutaneous, Mucosal, and Vulvovaginal Melanomas: Biology, Targeted Therapies, and Survival with a Focus on Immune Checkpoint Inhibitors"],"prefix":"10.3390","volume":"15","author":[{"given":"Danielle","family":"Christmas","sequence":"first","affiliation":[{"name":"Department of Gynaecological Oncology, Oxford University Hospitals, NHS Foundation Trust, Oxford OX3 9LE, UK"},{"name":"GynaeFellow Research Collaborative, Old Road, Oxford OX3 7LE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2801-2786","authenticated-orcid":false,"given":"Christina","family":"Pappa","sequence":"additional","affiliation":[{"name":"Department of Gynaecological Oncology, Oxford University Hospitals, NHS Foundation Trust, Oxford OX3 9LE, UK"},{"name":"GynaeFellow Research Collaborative, Old Road, Oxford OX3 7LE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Howell","sequence":"additional","affiliation":[{"name":"GynaeFellow Research Collaborative, Old Road, Oxford OX3 7LE, UK"},{"name":"Calderdale and Huddersfield, NHS Foundation Trust, Women\u2019s Health, Halifax HX3 0PW, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7106-0834","authenticated-orcid":false,"given":"Mohammad","family":"Daas","sequence":"additional","affiliation":[{"name":"GynaeFellow Research Collaborative, Old Road, Oxford OX3 7LE, UK"},{"name":"Department of Obstetrics and Gynaecology, Basildon and Thurrock University Hospital, Basildon SS16 5NL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3002-2079","authenticated-orcid":false,"given":"Keith","family":"Howell","sequence":"additional","affiliation":[{"name":"Leeds Cancer Centre, St James\u2019s University Hospital, Leeds Teaching Hospitals, Beckett Street, Leeds LS9 7TF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1885-6048","authenticated-orcid":false,"given":"Sunanda","family":"Dhar","sequence":"additional","affiliation":[{"name":"Department of Cellular Pathology, Oxford University Hospitals, NHS Foundation Trust, Oxford OX3 9LE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1485-8895","authenticated-orcid":false,"given":"Binamra","family":"Sigdel","sequence":"additional","affiliation":[{"name":"Department of Gynaecological Oncology, Oxford University Hospitals, NHS Foundation Trust, Oxford OX3 9LE, UK"},{"name":"GynaeFellow Research Collaborative, Old Road, Oxford OX3 7LE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv","family":"Manek","sequence":"additional","affiliation":[{"name":"Department of Cellular Pathology, Oxford University Hospitals, NHS Foundation Trust, Oxford OX3 9LE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8202-0969","authenticated-orcid":false,"given":"Moiad","family":"Alazzam","sequence":"additional","affiliation":[{"name":"Department of Gynaecological Oncology, Oxford University Hospitals, NHS Foundation Trust, Oxford OX3 9LE, UK"},{"name":"GynaeFellow Research Collaborative, Old Road, Oxford OX3 7LE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","article-title":"Cutaneous melanoma","volume":"402","author":"Long","year":"2023","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s40257-023-00795-3","article-title":"Global Incidence, Mortality, Risk Factors and Trends of Melanoma: A Systematic Analysis of Registries","volume":"24","author":"Huang","year":"2023","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41572-025-00603-8","article-title":"Cutaneous melanoma","volume":"11","author":"Tasdogan","year":"2025","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_5","first-page":"e70697","article-title":"Trends in Melanoma Incidence, Prevalence, Stage at Diagnosis, and Survival: An Analysis of the United States Cancer Statistics (USCS) Database","volume":"16","author":"Okobi","year":"2024","journal-title":"Cureus"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Chi, Z., Li, S., Sheng, X., Si, L., Cui, C., Han, M., and Guo, J. (2011). Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases. BMC Cancer, 11.","DOI":"10.1186\/1471-2407-11-85"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Carb\u00f3-Bagu\u00e9, A., Rubi\u00f3-Casadevall, J., Puigdemont, M., Sanvisens, A., Oliveras, G., Coll, M., Del Olmo, B., Perez-Bueno, F., and Marcos-Gragera, R. (2022). Epidemiology and Molecular Profile of Mucosal Melanoma: A Population-Based Study in Southern Europe. Cancers, 14.","DOI":"10.3390\/cancers14030780"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Clavero-Rovira, L., G\u00f3mez-Tom\u00e1s, \u00c1., Bassas-Freixas, P., Bodet, D., Ferrer, B., Hern\u00e1ndez-Losa, J., Munoz-Couselo, E., Perez-Benavente, A., Garcia-Patos, V., and Ferrandiz-Pulido, C. (2024). Mucosal Melanoma Clinical Management and Prognostic Implications: A Retrospective Cohort Study. Cancers, 16.","DOI":"10.3390\/cancers16010227"},{"key":"ref_9","first-page":"739","article-title":"Primary mucosal melanomas: A comprehensive review","volume":"5","author":"Mihajlovic","year":"2012","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jaad.2006.06.017","article-title":"Primary mucosal melanoma","volume":"56","author":"Patrick","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40257-019-00487-x","article-title":"Malignant Melanoma of the Vulva and Vagina: A US Population-Based Study of 1863 Patients","volume":"21","author":"Wohlmuth","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jaad.2015.10.015","article-title":"Epidemiology of genitourinary melanoma in the United States: 1992 through 2012","volume":"75","author":"Vyas","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lorenz, A., Koz\u0142owski, M., Lenkiewicz, S., Kwiatkowski, S., and Cymbaluk-P\u0142oska, A. (2022). Cutaneous Melanoma versus Vulvovaginal Melanoma\u2014Risk Factors, Pathogenesis and Comparison of Immunotherapy Efficacy. Cancers, 14.","DOI":"10.3390\/cancers14205123"},{"key":"ref_14","first-page":"4017","article-title":"Primary malignant melanomas of the female lower genital tract: Clinicopathological characteristics and management","volume":"10","author":"Wang","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3390\/clinpract14010018","article-title":"A Narrative Review of Current Knowledge on Cutaneous Melanoma","volume":"14","author":"Caraban","year":"2024","journal-title":"Clin. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6300329","DOI":"10.1155\/2022\/6300329","article-title":"TERT Promoter Mutations and Telomerase in Melanoma","volume":"2022","author":"Guo","year":"2022","journal-title":"J. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Indini, A., Roila, F., Grossi, F., Massi, D., and Mandal\u00e0, M. (2021). Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010147"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.semcancer.2019.09.013","article-title":"The mutational landscape of mucosal melanoma","volume":"61","author":"Nassar","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1038\/s41467-019-11107-x","article-title":"Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets","volume":"10","author":"Newell","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e179982","DOI":"10.1172\/jci.insight.179982","article-title":"Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma","volume":"9","author":"Vos","year":"2024","journal-title":"JCI Insight"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40257-021-00614-7","article-title":"Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment","volume":"22","author":"Wohlmuth","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ygyno.2024.06.002","article-title":"A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma","volume":"188","author":"Wilhite","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejca.2022.04.018","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment-Update 2022","volume":"170","author":"Garbe","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1097\/AOG.0b013e3181fb8045","article-title":"Primary Malignant Melanoma of the Vagina","volume":"116","author":"Frumovitz","year":"2010","journal-title":"Obstet. Gynecol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jogc.2018.07.011","article-title":"Melanoma of the Vulva and Vagina: Surgical Management and Outcomes Based on a Clinicopathologic Reviewof 68 Cases","volume":"41","author":"Sinasac","year":"2019","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bjps.2024.10.035","article-title":"Clinicopathologic features and surgical management in vulvovaginal melanoma\u2014A retrospective single-center study","volume":"100","author":"Lumiala","year":"2025","journal-title":"J. Plast. Reconstr. Aesthet. Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/IGC.0000000000000013","article-title":"Primary Malignant Melanoma of the Vagina","volume":"24","author":"Xia","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_29","first-page":"410","article-title":"Comprehensive management of vulvovaginal cancers","volume":"75","author":"Oonk","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/ijgc-2023-004486","article-title":"European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer-Update 2023","volume":"33","author":"Oonk","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ygyno.2023.01.011","article-title":"Lymphatic mapping and sentinel node biopsy in vulvar melanoma: The first multicenter study and systematic review","volume":"170","author":"Collarino","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB\u2013C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"EVIDoa2200214","DOI":"10.1056\/EVIDoa2200214","article-title":"Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma","volume":"1","author":"Eggermont","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1200\/JCO.22.00533","article-title":"Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)","volume":"41","author":"Weber","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1158\/1078-0432.CCR-22-3207","article-title":"SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma","volume":"29","author":"Kottschade","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.annonc.2022.07.002","article-title":"Toripalimab (anti-PD-1) versus high-dose interferon-\u03b12b as adjuvant therapy in resected mucosal melanoma: A phase II randomized trial","volume":"33","author":"Lian","year":"2022","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"103503","DOI":"10.1016\/j.critrevonc.2021.103503","article-title":"Adjuvant systemic treatment for high-risk resected non-cutaneous melanomas: What is the evidence?","volume":"167","author":"Yong","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1007\/s00432-022-04090-2","article-title":"Chemotherapy in combination with anti-PD-1 agents as adjuvant therapy for high-risk oral mucosal melanoma","volume":"149","author":"Wu","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.3802\/jgo.2020.31.e66","article-title":"Vulvar melanoma: An analysis of prognostic factors and treatment patterns","volume":"31","author":"Albert","year":"2020","journal-title":"J. Gynecol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1200\/JCO.23.01136","article-title":"Systemic Therapy for Melanoma: ASCO Guideline Update","volume":"41","author":"Seth","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ejca.2021.08.015","article-title":"c-KIT inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: A systematic review and one-arm meta-analysis","volume":"157","author":"Steeb","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/s41416-022-01942-z","article-title":"Clinical and genomic correlates of imatinib response in melanomas with KIT alterations","volume":"127","author":"Jung","year":"2022","journal-title":"Br. J. Cancer."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMra2034861","article-title":"Recent Advances in the Treatment of Melanoma","volume":"384","author":"Curti","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1158\/1078-0432.CCR-13-0739","article-title":"Phase II Randomized Trial Comparing High-Dose IFN-\u03b12b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma","volume":"19","author":"Lian","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1158\/1078-0432.CCR-21-0809","article-title":"5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study","volume":"27","author":"Ascierto","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/JCO.21.02961","article-title":"Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients with Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00262-019-02351-7","article-title":"Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma","volume":"68","author":"Rossoni","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41416-018-0207-6","article-title":"Antitumour activity of pembrolizumab in advanced mucosal melanoma: A post-hoc analysis of KEYNOTE-001, 002, 006","volume":"119","author":"Hamid","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and Safety of Nivolumab Alone or in Combination with Ipilimumab in Patients with Mucosal Melanoma: A Pooled Analysis","volume":"35","author":"Larkin","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.annonc.2022.06.004","article-title":"Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: An international, retrospective, cohort study","volume":"33","author":"Dimitriou","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/LGT.0000000000000583","article-title":"Clinical Characteristics and Treatment Response with Checkpoint Inhibitors in Malignant Melanoma of the Vulva and Vagina","volume":"25","author":"Wohlmuth","year":"2021","journal-title":"J. Low. Genit. Tract Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.3802\/jgo.2019.30.e94","article-title":"Investigating the role of immunotherapy in advanced\/recurrent female genital tract melanoma: A preliminary experience","volume":"30","author":"Indini","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Paolino, G., Huber, V., Camerini, S., Casella, M., Macone, A., Bertuccini, L., Iosi, F., Moliterni, E., Cecchetti, S., and Ruspantini, I. (2021). The Fatty Acid and Protein Profiles of Circulating CD81-Positive Small Extracellular Vesicles Are Associated with Disease Stage in Melanoma Patients. Cancers, 13.","DOI":"10.20944\/preprints202105.0577.v1"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/11\/551\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T11:14:16Z","timestamp":1762946056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/11\/551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":61,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["jpm15110551"],"URL":"https:\/\/doi.org\/10.3390\/jpm15110551","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]}}}